J&J | JNJ - Net Income


J&J reported $5.24B in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Abbott USD 1.08B 699M Mar/2026
Amgen USD 1.82B 486M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Baxter International USD -15M 1.11B Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
Becton, Dickinson and Co. USD -311M 693M Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
Boston Scientific USD 1.34B 669M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
CONMED USD 13.83M 2.91M Mar/2026
Cooper Companies USD -77.9M 208.7M Mar/2026
Dexcom USD 199.5M 67.8M Mar/2026
Edwards Lifesciences USD 380.7M 289.5M Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Globus Medical USD 140.59M 21.63M Dec/2025
Insulet USD 91.1M 10.5M Mar/2026
Integra LifeSciences USD -4.62M 2.91M Mar/2026
Intuitive Surgical USD 821.5M 26.7M Mar/2026
J&J USD 5.24B 119M Mar/2026
Medtronic USD 1.24B 100M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Merit Medical Systems USD 41M 2.99M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
Stryker USD 745M 104M Mar/2026
Tandem Diabetes Care USD -589K 20.58M Dec/2025
Teva Pharmaceutical Industries USD 369M 111M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026
Zimmer Biomet Holdings USD 238.1M 98.8M Mar/2026
Zoetis USD 601M 2M Mar/2026